| General Information | |
|---|---|
| ZINC ID | ZINC000040424407 |
| Molecular Weight (Da) | 476 |
| SMILES | CCN1C(c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)c2C)=NC(=O)C1(C)C |
| Molecular Formula | C23Cl3N4O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.533 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| LogP | 7.255 |
| Activity (Ki) in nM | 1174.898 |
| Polar Surface Area (PSA) | 50.49 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.94910711 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.26 |
| Ilogp | 3.91 |
| Xlogp3 | 6.21 |
| Wlogp | 5.43 |
| Mlogp | 5.21 |
| Silicos-it log p | 6.59 |
| Consensus log p | 5.47 |
| Esol log s | -6.84 |
| Esol solubility (mg/ml) | 0.0000681 |
| Esol solubility (mol/l) | 0.00000014 |
| Esol class | Poorly sol |
| Ali log s | -7.06 |
| Ali solubility (mg/ml) | 0.0000419 |
| Ali solubility (mol/l) | 0.00000008 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.17 |
| Silicos-it solubility (mg/ml) | 0.00000032 |
| Silicos-it solubility (mol/l) | 6.75E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.79 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.76 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.825 |
| Logd | 4.801 |
| Logp | 5.659 |
| F (20%) | 0.002 |
| F (30%) | 0.003 |
| Mdck | 9.20E-06 |
| Ppb | 0.9805 |
| Vdss | 0.763 |
| Fu | 0.0227 |
| Cyp1a2-inh | 0.209 |
| Cyp1a2-sub | 0.945 |
| Cyp2c19-inh | 0.923 |
| Cyp2c19-sub | 0.816 |
| Cl | 4.163 |
| T12 | 0.08 |
| H-ht | 0.231 |
| Dili | 0.966 |
| Roa | 0.385 |
| Fdamdd | 0.486 |
| Skinsen | 0.038 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.395 |
| Bcf | 3.806 |
| Igc50 | 5.044 |
| Lc50 | 6.908 |
| Lc50dm | 6.154 |
| Nr-ar | 0.004 |
| Nr-ar-lbd | 0.009 |
| Nr-ahr | 0.865 |
| Nr-aromatase | 0.97 |
| Nr-er | 0.577 |
| Nr-er-lbd | 0.024 |
| Nr-ppar-gamma | 0.023 |
| Sr-are | 0.841 |
| Sr-atad5 | 0.013 |
| Sr-hse | 0.033 |
| Sr-mmp | 0.889 |
| Sr-p53 | 0.888 |
| Vol | 444.184 |
| Dense | 1.067 |
| Flex | 0.174 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 1 |
| Qed | 0.452 |
| Synth | 2.873 |
| Fsp3 | 0.261 |
| Mce-18 | 55.862 |
| Natural product-likeness | -0.965 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |